Course duration
5–10 consecutive days per course, per the clinical literature.
Protocol / Research Dosing Guide
Thymalin Dosage Guide: Russian Clinical Literature, Route and Reconstitution
An evidence-organized Thymalin reference separating the Russian clinical-literature intramuscular course protocol from community subcutaneous reports and keeping the extract's mixed-peptide composition clearly distinguished from single-sequence thymic peptides.
Last reviewed September 16, 202616 minute readResearch information only
Level 2 — Decades-old, single-country clinical literatureNot independently replicated in the WestNot FDA approved
Thymalin Quick Start
Thymalin is a Soviet-era thymus extract fraction developed in the 1970s–80s, used clinically in Russia as an immunocorrector. Because it is a mixture of low-molecular-weight peptides rather than one defined molecule, batch composition is not standardized the way a synthetic single-sequence peptide is. The published dose figures describe historical Russian clinical practice, largely from one research group, and have not been independently replicated in Western trials. Thymalin should not be confused with thymulin (FTS), a single zinc-dependent nonapeptide, or with thymosin alpha-1, a distinct 28-amino-acid defined peptide.
Why researchers care
Immune modulation and geroprotection research interest
Class
Polypeptide fraction extracted from thymus tissue (a mixture of low-molecular-weight peptides, not a single defined sequence)
Route reported
Intramuscular in the published Russian clinical literature; subcutaneous is a community-reported, non-trial route
Cycle length
5–10 consecutive daily doses per course, courses repeated roughly every 6 months in the reviewed literature
Regulatory status
Not FDA approved; not approved in the EU or UK; used clinically in Russia as an immunocorrector
Loading supplier information
Thymalin Dosing Protocol and Schedule
The supplied source reports that the Russian clinical literature centers on 5–10 mg intramuscular once daily for a short course of 5–10 consecutive days, repeated after roughly six months, reconstituted in saline or procaine. It reports that community and research-chemical sources instead describe subcutaneous use at loosely similar per-course amounts, but states plainly that the subcutaneous route has no controlled-trial basis.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Standard course (Russian clinical literature) | 5–10 mg intramuscular once daily | Human clinical literature (Russian) |
| Course length | 5–10 consecutive days | Human clinical literature (Russian) |
| Course repetition (geroprotection reports) | Roughly every 6 months | Human clinical literature (Russian) |
| Strongest mortality-signal pattern reported | Annually repeated courses over several years | Human clinical literature (Russian, single cohort) |
| Community subcutaneous use | Loosely similar per-course amounts, subcutaneous | Community reported |
| Rest period between courses | Roughly 6 months as reported in the geroprotection literature | Human clinical literature (Russian) |
All dose and course figures above trace to Russian-language clinical literature from one research group and have not been independently replicated in Western trials. The intramuscular route is what was actually studied; the subcutaneous route reported in community and research-chemical sources has no controlled-trial basis of its own.
Thymalin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled 10 mg vial
Research planning item
Bacteriostatic water or sterile saline at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label with the preparation date
Thymalin Reconstitution Calculator
Vial-format concentration math
Concentration
10 mg/mL
Draw volume
0.5 mL
U-100 units
50
Mathematical draws
2
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Thymalin: Morning or Night?
Morning or evening?
Not established in the sources reviewed; the literature reports once-daily dosing without specifying time of day.
Daily or spaced?
The literature describes daily dosing for 5–10 consecutive days per course, not a spaced schedule.
With food?
Not applicable to an injected product.
Missed amount?
No validated replacement procedure exists within a course.
Thymalin Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Intramuscular | Powder reconstituted in saline or procaine, per the Russian clinical literature | The only route with the underlying clinical-literature dose data |
| Subcutaneous | Common in community and research-chemical sources at loosely similar amounts | No controlled-trial basis for this route |
| Oral | Not viable | No exposure data |
| Route conversion | Not established | Intramuscular dose figures cannot be assumed to transfer directly to subcutaneous use |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Thymalin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established in the sources reviewed | No human pharmacokinetic study was identified |
| Course-repetition basis | Roughly every 6 months in the geroprotection reports | Reported as a clinical-cohort pattern, not a pharmacokinetic finding |
| Batch consistency | Not standardized, since Thymalin is an extract fraction rather than a single sequence | Affects reproducibility across sources |
| Frequency logic | Once daily during the course is the literature-reported pattern | Not derived from a stated half-life figure |
Thymalin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Intramuscular | 5 mg | Once daily, 5–10 day course | Human clinical literature (Russian) | No |
| Intramuscular | 10 mg | Once daily, 5–10 day course | Human clinical literature (Russian) | No |
| Subcutaneous | Loosely similar per-course amounts | Once daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Thymalin Reconstitution Guide
Concentration: 10 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 5 mg | 0.5 mL | 50 units |
| 10 mg | 1 mL | 100 units |
- 1.Confirm the exact quantity printed on the vial (commonly 10 mg).
- 2.Choose and record the diluent volume; 10 mg into 1 mL gives 10 mg/mL.
- 3.Clean the stopper with an alcohol swab.
- 4.Add the liquid slowly down the vial wall.
- 5.Swirl gently until clear; never shake.
- 6.Inspect for cloudiness, discoloration or particles and discard anything that is not clear.
- 7.Label the vial with the calculated concentration and preparation date.
- 8.Refrigerate at 2–8°C and use only the calculated concentration for arithmetic.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Thymalin Works
Composition
Thymalin is a polypeptide fraction extracted from thymus tissue, a mixture of low-molecular-weight peptides rather than a single defined sequence.
Thymalin Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved; not approved in the EU or UK; used clinically in Russia as an immunocorrector
- Morozov VG, Khavinson VKh (1997) described natural and synthetic thymic peptides, including Thymalin, as therapeutics for immune dysfunction.
- Khavinson VKh, Morozov VG (2002, 2003) reported a geroprotective effect and prolonged survival associated with repeated Thymalin and epithalamin courses in a single research cohort of 266 subjects; the 2003 report describes the same cohort as the 2002 report and is not an independent replication.
- Khavinson VKh, Linkova NS, et al. (2020) reported that Thymalin activates differentiation of human hematopoietic stem cells in laboratory research.
- Linkova N, Khavinson V, et al. (2023) examined dipeptide components of Thymalin in relation to gene expression and protein synthesis pathways relevant to COVID-19 pathogenesis, a mechanistic laboratory analysis rather than a clinical outcomes trial.
Who Should Avoid Thymalin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No established protocol outside the reviewed adult clinical literature
Active autoimmune disease
Immune-modulating mechanism raises theoretical concern not addressed in the reviewed literature
Anyone relying on subcutaneous use for equivalence to the studied intramuscular route
The subcutaneous route has no controlled-trial basis
Concurrent immune-affecting medicines without clinician review
No interaction studies were identified
Expectation of independently replicated Western safety data
The literature is single-country and largely one research group
Thymalin Side Effects, Risks and Safety
Injection-site reactionsAnecdotal
Important limitation: No controlled incidence data for either route in the sources reviewed.
Immune-related effectsReported as the intended mechanism
Important limitation: Direction and magnitude of any adverse immune effect are not characterized in the sources reviewed.
Long-term safetyNot independently evaluated in modern settings
Important limitation: The literature reflects older Russian clinical use without independent modern safety review.
Batch-to-batch variabilityInherent to an extract fraction
Important limitation: Not addressed as a safety variable in the sources reviewed.
Drug interactionsUnknown
Important limitation: No interaction studies were identified.
Subcutaneous-route safety specificallyUnknown
Important limitation: No controlled study of this route was identified.
Thymalin Timeline and Monitoring
Course repetition interval
Roughly every 6 months in the geroprotection reports, with annual repetition described as the strongest mortality-signal pattern.
Onset within a course
Not established as a specific figure in the sources reviewed.
Monitoring
No validated monitoring schedule or stopping rule was identified in the sources reviewed.
Thymalin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Immunocorrection (Russian clinical use) | Established in Russian clinical practice | Decades of Russian clinical literature | Not independently replicated in Western trials |
| Geroprotection / survival signal | Reported in one Russian research cohort | Single-group, decades-old, Russian-language cohort data | Not independently confirmed |
| Hematopoietic stem cell differentiation | Laboratory finding | In vitro human cell research | Not a clinical outcome |
| COVID-19-related gene expression effects | Laboratory/mechanistic finding | Gene expression and protein synthesis analysis | Not a clinical outcomes trial |
Thymalin Storage and Handling
Lyophilized powder
No independently verified modern stability study was identified; follow the exact product label.
Prepared vial
Community reconstitution guides describe refrigeration at 2–8°C after mixing.
Appearance
A clear, colorless solution is expected; cloudiness or particles mean discard.
Batch labeling
Because Thymalin is an extract, confirm the exact labeled quantity and source for every vial rather than assuming uniformity.
Thymalin Troubleshooting
Confusing Thymalin with thymulin or thymosin alpha-1
These are three distinct compounds; Thymalin is a mixed extract fraction, not a single defined sequence like the other two.
Solution appears cloudy
Discard; do not use a non-clear solution.
Calculated units look wrong
Recheck vial quantity, diluent volume, target amount, and syringe conversion.
Uncertain about intramuscular vs subcutaneous
The clinical-literature dose data is intramuscular only; subcutaneous use has no controlled-trial basis.
A scheduled amount is missed within a course
No validated missed-amount procedure exists in the sources reviewed.
Thymalin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Thymalin | Mixed thymus extract fraction | Russian clinical literature, single research group | Not FDA approved |
| Thymulin (FTS) | Single zinc-dependent nonapeptide | Distinct evidence base | Not FDA approved |
| Thymosin Alpha-1 | Single defined 28-amino-acid peptide | Broader international clinical study history | Not FDA approved in the U.S. as of the sources reviewed |
| Epitalon | Pineal-derived bioregulator peptide | Studied alongside Thymalin in the same Russian research program | Not FDA approved |
Thymalin Frequently Asked Questions
What is Thymalin?
A polypeptide fraction extracted from thymus tissue — a mixture of low-molecular-weight peptides, not a single defined molecule.
What dose does the clinical literature describe?
5–10 mg intramuscular once daily, as a course of 5–10 consecutive days, reconstituted in saline or procaine.
Is Thymalin the same as thymulin or thymosin alpha-1?
No. All three are distinct compounds: Thymalin is a mixed extract, thymulin (FTS) is a single zinc-dependent nonapeptide, and thymosin alpha-1 is a defined 28-amino-acid peptide.
What route do the published protocols use?
Intramuscular. Subcutaneous use is commonly described by community and research-chemical sources but has no controlled-trial basis.
How often were courses repeated in the studies?
Roughly every 6 months, with the strongest mortality signal tied to annually repeated courses over several years in one research cohort.
How is Thymalin reconstituted?
It is supplied as a lyophilized powder. Original protocols used sterile saline or procaine; community guides describe 2 mL bacteriostatic water per 10 mg vial.
Is Thymalin approved in the West?
No. It is not FDA approved and not approved in the EU or UK; it is used clinically in Russia as an immunocorrector.
Is the geroprotection data independently confirmed?
No. The 2002 and 2003 reports describe the same 266-subject cohort from one research group, not an independent replication.
What is Thymalin's half-life?
Not established in the sources reviewed.
Is long-term modern safety data available?
No. The literature reflects older Russian clinical use without independent modern safety evaluation.
What does the calculator do?
It converts entered vial and liquid values into concentration and syringe-volume arithmetic only.
Sources and Research
Human clinical literature (Russian)
1. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction
Overview of Thymalin and related thymic peptides in immune dysfunction.
Open direct sourceHuman clinical literature (Russian, single cohort)
2. Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin
Single-cohort survival data for repeated Thymalin and epithalamin courses.
Open direct sourceHuman clinical literature (Russian, same cohort)
3. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life
Describes the same 266-subject cohort as the 2002 report; not an independent replication.
Open direct sourceLaboratory research
4. Khavinson VKh, Linkova NS, et al. Thymalin: activation of differentiation of human hematopoietic stem cells
Laboratory research on stem cell differentiation.
Open direct sourceLaboratory research
5. Linkova N, Khavinson V, et al. The influence of KE and EW dipeptides in the composition of the thymalin drug on gene expression and protein synthesis involved in the pathogenesis of COVID-19
Mechanistic gene-expression analysis of Thymalin's dipeptide components.
Open direct sourceMissing information flagged for review
- Independent Western replication of the Russian clinical and geroprotection data: Not established
- Human pharmacokinetics and half-life: Not established
- Controlled-trial data for the subcutaneous route: Not established
- Standardized batch composition data across extract sources: Not established
- Long-term modern safety data: Not established